title: Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.
abstract: Human melanoma cells can process the MAGE-1 gene product and present the processed nonapeptide EADPTGHSY on their major histocompatibility complex class I molecules, HLA-A1, as a determinant for cytolytic T lymphocytes (CTLs). Considering that autologous antigen presenting cells (APCs) pulsed with the synthetic nonapeptide might, therefore, be immunogenic, melanoma patients whose tumor cells express the MAGE-1 gene and who are HLA-A1+ were immunized with a vaccine made of cultured autologous APCs pulsed with the synthetic nonapeptide. Analyses of the nature of the in vivo host immune response to the vaccine revealed that the peptide-pulsed APCs are capable of inducing autologous melanoma-reactive and the nonapeptide-specific CTLs in situ at the immunization site and at distant metastatic disease sites.
authors.affiliation: Department of Medicine, University of Connecticut School of Medicine, Farmington 06030, USA.
authors.forename: B
authors.initials: B
authors.lastname: Mukherji
authors.forename: N G
authors.initials: NG
authors.lastname: Chakraborty
authors.forename: S
authors.initials: S
authors.lastname: Yamasaki
authors.forename: T
authors.initials: T
authors.lastname: Okino
authors.forename: H
authors.initials: H
authors.lastname: Yamase
authors.forename: J R
authors.initials: JR
authors.lastname: Sporn
authors.forename: S K
authors.initials: SK
authors.lastname: Kurtzman
authors.forename: M T
authors.initials: MT
authors.lastname: Ergin
authors.forename: J
authors.initials: J
authors.lastname: Ozols
authors.forename: J
authors.initials: J
authors.lastname: Meehan
mesh_terms: D000595:Amino Acid Sequence; D000938:Antigen-Presenting Cells / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000096:biosynthesis*; D002460:Cell Line; D015870:Gene Expression; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D015788:HLA-A1 Antigen / Q000032:analysis / Q000096:biosynthesis / Q000737:chemistry; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008545:Melanoma / Q000276:immunology* / Q000628:therapy; D058950:Melanoma-Specific Antigens; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins; D010446:Peptide Fragments / Q000276:immunology*; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D015788:HLA-A1 Antigen; C072011:MAGEA1 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D016178:Granulocyte-Macrophage Colony-Stimulating Factor